News

The trial assessed the safety and tolerability of Neurodex, a proprietary formulation of dextromethorphan and low dose quinidine. Patient assessments also demonstrated statistically significant improvements in sleep, present

The company submitted the application in late July and, pending regulatory approval, expects to launch zileuton CR in the second half of 2007. The new drug application includes

Under the terms of the agreement, Lilly will acquire all of the outstanding shares of Icos common stock at a price of $32 per share. The move by

The designation was granted for the use of Genasense for patients with stage IV malignant melanoma. Orphan drug designation is intended to facilitate the development of drugs that

An investigational new drug application was filed in September 2006 with the FDA for MEM 3454. The FDA has advised the company that it needs more explanation for

The study was authored by UCSF and Rush University Medical Center. CERE-120 carries the gene for neurturin, a naturally occurring protein, whose role is to keep dopamine-secreting neurons

The agreement includes InterMune's lead compound ITMN-191, which is expected to enter clinical trials before the end of the year. The companies will also collaborate on a research

LX2931 is a small molecule compound with potential application in the treatment of diseases such as multiple sclerosis and rheumatoid arthritis. In preclinical research, LX2931 significantly reduced inflammatory

The study will evaluate the safety and preliminary anti-tumor activity of Interleukin 21 (IL-21) in combination with Nexavar. “Our preclinical data have demonstrated that IL-21 can be additive,